Unlock this StockReport nowClick to Unlock

Read Gene SA

RDG PLN0.64 -0.0  -1.5%
15/01/19

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 TTM 2018E 2019E CAGR / Avg
Revenue PLNm
Operating Profit PLNm
Net Profit PLNm
EPS Reported PLN
EPS Normalised PLN
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps PLN
Capex ps PLN
Free Cashflow ps PLN
Dividends
Dividend ps PLN
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc PLNm
Working Capital PLNm
Net Fixed Assets PLNm
Net Debt PLNm
Book Value PLNm
Average Shares m
Book Value ps PLN -2.9%

FINANCIAL BRIEF: For the nine months ended 30 September 2018, Read-Gene SA revenues decreased 41% to PLN2M. Net loss increased from PLN653K to PLN1.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Operating Expense Total increase of 15% to PLN4.7M (expense), Interest Expense/Income - Net decrease from PLN7K (income) to PLN1K (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score  
E+
E+
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 30th Sep '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2018
31st Dec 2019

Price Target: N/A
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a () () () () () ()
Consensus Estimate
1m Change
3m Change
Broker Consensus Trend
Broker Recommendations for Read Gene SA
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
There are no named brokers.

Profile Summary

Read-Gene SA is a Poland-based company active in the biotechnology sector. It is focused on technologies which aim is to detect, prevent and treat malignant tumors. The Company specializes in three fields: chemoprevention, clinical trials and genetic testing. It offers breast cancer, colon cancer and prostate cancer tests, as well as, medical consultancy, DNA tests and supplements. The Company operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o. Its major shareholder is GEN-PAT-MED Sp. z o.o.

Directors: Bronislaw Ziemianin (CSU) , Jan Lubinski (CMG) 65, Tomasz Huzarski (VSU) , Cezary Cybulski (OTH) 63, Karolina Ertmanska (OTH) , Adam Gliszczynski (SUB) , Jacek Gronwald (SUB) , Janusz Pirog (SUB) , Adam Szuba (SUB) , Dariusz Wiecaszek (SUB) ,

No. of Employees: 11 No. of Shareholders: n/a


Last Annual December 31st, 2017
Last Interim September 30th, 2018
Incorporated September 27, 2005
Public Since February 12, 2009
Shares in Issue 9,449,731
Free Float 9.36m (99.0%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Warsaw Stock Exchange
Eligible for an ISA? a SIPP?

RDG Share Price Performance RDGQuote
PLN0.64
-0.0  -1.5%
Traded 4:35pm · Minimum 15 min delayed · NMS:

Latest RDG News Announcements (delayed)

Upcoming RDG Events

Recent ↓
Tuesday 26th June, 2018
Read Gene SA Annual Shareholders Meeting
Tuesday 20th June, 2017
Read Gene SA Annual Shareholders Meeting
Wednesday 27th July, 2016
Read Gene SA Extraordinary Shareholders Meeting
Monday 27th June, 2016
Read Gene SA Extraordinary Shareholders Meeting
Tuesday 23rd June, 2015
Read Gene SA Annual Shareholders Meeting


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.


Should you buy RDG

Access RDG Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis